Genocea Biosciences Inc (NASDAQ:GNCA) stock ended lower on Friday on high volume after the company released data.
Market Reaction
As of 8:29, GNCA stock fell 3.33% to $2.32. The stock traded more than 333K shares, well above its average volume of 312K shares.
Major Trigger:
Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021
Key Highlights:
- presents updated immunogenicity and clinical response data from the GEN-009 Phase 1 trial that continue to validate the company’s unique and differentiated approach to identifying clinically meaningful immunotherapy targets through the proprietary ATLAS selection process.
- Data on the neoantigen vaccine combined with PD-1 inhibition in advanced solid tumors will be shared by Maura Gillison, M.D., Ph.D., Lead Investigator, MD Anderson Cancer Center, during a poster presentation (Abstract #2613) at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021. The poster is available for on-demand viewing on the ASCO website and also posted to the Scientific Resources section of the Genocea website here.
- Long-term results demonstrate that GEN-009 continues to generate broad immune responses against neoantigens that can lead to sustained clinical responses. In Part A of the study, designed to measure safety and immunogenicity only, eight patients with no measurable disease were vaccinated with GEN-009 as a monotherapy.
- Six of the eight patients continue without recurrence with a median follow up of 25 months post start of the vaccination. Notably, as previously reported, GEN-009 elicited T cell immune responses to 99% of the ATLAS-selected neoantigens, the highest seen across neoantigen vaccine programs.
 In News){kind=link}